Cargando…

History of autoimmune conditions and lymphoma prognosis

Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleinstern, Geffen, Maurer, Matthew J., Liebow, Mark, Habermann, Thomas M., Koff, Jean L., Allmer, Cristine, Witzig, Thomas E., Nowakowski, Grzegorz S., Micallef, Ivana N., Johnston, Patrick B., Inwards, David J., Thompson, Carrie A., Feldman, Andrew L., Link, Brian K., Flowers, Christopher, Slager, Susan L., Cerhan, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070501/
https://www.ncbi.nlm.nih.gov/pubmed/30069001
http://dx.doi.org/10.1038/s41408-018-0105-4
_version_ 1783343677143252992
author Kleinstern, Geffen
Maurer, Matthew J.
Liebow, Mark
Habermann, Thomas M.
Koff, Jean L.
Allmer, Cristine
Witzig, Thomas E.
Nowakowski, Grzegorz S.
Micallef, Ivana N.
Johnston, Patrick B.
Inwards, David J.
Thompson, Carrie A.
Feldman, Andrew L.
Link, Brian K.
Flowers, Christopher
Slager, Susan L.
Cerhan, James R.
author_facet Kleinstern, Geffen
Maurer, Matthew J.
Liebow, Mark
Habermann, Thomas M.
Koff, Jean L.
Allmer, Cristine
Witzig, Thomas E.
Nowakowski, Grzegorz S.
Micallef, Ivana N.
Johnston, Patrick B.
Inwards, David J.
Thompson, Carrie A.
Feldman, Andrew L.
Link, Brian K.
Flowers, Christopher
Slager, Susan L.
Cerhan, James R.
author_sort Kleinstern, Geffen
collection PubMed
description Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for sex, prognostic score, and treatment. History of any of the eight autoimmune conditions ranged from 7.4% in HL to 18.2% in MZL, and was not associated with EFS or OS for any lymphoma subtype. However, there was a positive association of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.23, CI: 1.15–4.34) and HL (HR = 2.63, CI: 1.04–6.63), which was largely driven by rheumatoid arthritis. Autoimmune conditions primarily mediated by T-cell responses were not found to be associated with EFS or OS in any lymphoma subtype, although there were few events for this exposure. Our results indicate that distinguishing autoimmune conditions primarily mediated by B-cell/T-cell responses may yield insight regarding the impact of this comorbid disease, affecting ~10% of lymphoma patients, on survival.
format Online
Article
Text
id pubmed-6070501
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60705012018-08-02 History of autoimmune conditions and lymphoma prognosis Kleinstern, Geffen Maurer, Matthew J. Liebow, Mark Habermann, Thomas M. Koff, Jean L. Allmer, Cristine Witzig, Thomas E. Nowakowski, Grzegorz S. Micallef, Ivana N. Johnston, Patrick B. Inwards, David J. Thompson, Carrie A. Feldman, Andrew L. Link, Brian K. Flowers, Christopher Slager, Susan L. Cerhan, James R. Blood Cancer J Article Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for sex, prognostic score, and treatment. History of any of the eight autoimmune conditions ranged from 7.4% in HL to 18.2% in MZL, and was not associated with EFS or OS for any lymphoma subtype. However, there was a positive association of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.23, CI: 1.15–4.34) and HL (HR = 2.63, CI: 1.04–6.63), which was largely driven by rheumatoid arthritis. Autoimmune conditions primarily mediated by T-cell responses were not found to be associated with EFS or OS in any lymphoma subtype, although there were few events for this exposure. Our results indicate that distinguishing autoimmune conditions primarily mediated by B-cell/T-cell responses may yield insight regarding the impact of this comorbid disease, affecting ~10% of lymphoma patients, on survival. Nature Publishing Group UK 2018-08-01 /pmc/articles/PMC6070501/ /pubmed/30069001 http://dx.doi.org/10.1038/s41408-018-0105-4 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Kleinstern, Geffen
Maurer, Matthew J.
Liebow, Mark
Habermann, Thomas M.
Koff, Jean L.
Allmer, Cristine
Witzig, Thomas E.
Nowakowski, Grzegorz S.
Micallef, Ivana N.
Johnston, Patrick B.
Inwards, David J.
Thompson, Carrie A.
Feldman, Andrew L.
Link, Brian K.
Flowers, Christopher
Slager, Susan L.
Cerhan, James R.
History of autoimmune conditions and lymphoma prognosis
title History of autoimmune conditions and lymphoma prognosis
title_full History of autoimmune conditions and lymphoma prognosis
title_fullStr History of autoimmune conditions and lymphoma prognosis
title_full_unstemmed History of autoimmune conditions and lymphoma prognosis
title_short History of autoimmune conditions and lymphoma prognosis
title_sort history of autoimmune conditions and lymphoma prognosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070501/
https://www.ncbi.nlm.nih.gov/pubmed/30069001
http://dx.doi.org/10.1038/s41408-018-0105-4
work_keys_str_mv AT kleinsterngeffen historyofautoimmuneconditionsandlymphomaprognosis
AT maurermatthewj historyofautoimmuneconditionsandlymphomaprognosis
AT liebowmark historyofautoimmuneconditionsandlymphomaprognosis
AT habermannthomasm historyofautoimmuneconditionsandlymphomaprognosis
AT koffjeanl historyofautoimmuneconditionsandlymphomaprognosis
AT allmercristine historyofautoimmuneconditionsandlymphomaprognosis
AT witzigthomase historyofautoimmuneconditionsandlymphomaprognosis
AT nowakowskigrzegorzs historyofautoimmuneconditionsandlymphomaprognosis
AT micallefivanan historyofautoimmuneconditionsandlymphomaprognosis
AT johnstonpatrickb historyofautoimmuneconditionsandlymphomaprognosis
AT inwardsdavidj historyofautoimmuneconditionsandlymphomaprognosis
AT thompsoncarriea historyofautoimmuneconditionsandlymphomaprognosis
AT feldmanandrewl historyofautoimmuneconditionsandlymphomaprognosis
AT linkbriank historyofautoimmuneconditionsandlymphomaprognosis
AT flowerschristopher historyofautoimmuneconditionsandlymphomaprognosis
AT slagersusanl historyofautoimmuneconditionsandlymphomaprognosis
AT cerhanjamesr historyofautoimmuneconditionsandlymphomaprognosis